1. Aubin RG, Troisi EC, Montelongo J, Alghalith AN, Nasrallah MP, Santi M, Camara PG. Pro-inflammatory cytokines mediate the epithelial-to-mesenchymal-like transition of pediatric posterior fossa ependymoma. Nat Commun 2022; 13: 3936.
2.
Chen PY, Qin L, Simons M. TGFbeta signaling pathways in human health and disease. Front Mol Biosci 2023; 10: 1113061.
3.
Colak S, Ten Dijke P. Targeting TGF-beta signaling in cancer. Trends Cancer 2017; 3: 56-71.
4.
Cunningham R, Hansen CG. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clin Sci (Lond) 2022; 136: 197-222.
5.
Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-584.
6.
Dey A, Varelas X, Guan KL. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov 2020; 19: 480-494.
7.
Eder N, Roncaroli F, Domart MC, Horswell S, Andreiuolo F, Flynn HR, Lopes AT, Claxton S, Kilday JP, Collinson L, Mao JH, Pietsch T, Thompson B, Snijders AP, Ultanir SK. YAP1/TAZ drives ependymoma-like tumour formation in mice. Nat Commun 2020; 11: 2380.
8.
Fan C, Wang Q, Kuipers TB, Cats D, Iyengar PV, Hagenaars SC, Mesker WE, Devilee P, Tollenaar R, Mei H, Ten Dijke P. LncRNA LITATS1 suppresses TGF-beta-induced EMT and cancer cell plasticity by potentiating TbetaRI degradation. EMBO J 2023; 42: e112806.
9.
Garcia-Rendueles AR, Rodrigues JS, Garcia-Rendueles ME, Suarez-Fariña M, Perez-Romero S, Barreiro F, Bernabeu I, Rodriguez-Garcia J, Fugazzola L, Sakai T, Liu F, Cameselle-Teijeiro J, Bravo SB, Alvarez CV. Rewiring of the apoptotic TGF-beta-SMAD/NFkappaB pathway through an oncogenic function of p27 in human papillary thyroid cancer. Oncogene 2017; 36: 652-666.
10.
Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A, Wang M, Handler MH, Foreman NK. Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol 2013; 191: 4880-4888.
11.
Griesinger AM, Josephson RJ, Donson AM, Mulcahy Levy JM,Amani V, Birks DK, Hoffman LM, Furtek SL, Reigan P, Handler MH, Vibhakar R, Foreman NK. Interleukin-6/STAT3 pathway signaling drives an inflammatory phenotype in group A ependymoma. Cancer Immunol Res 2015; 3: 1165-1174.
12.
Hu X, Wu X, Berry K, Zhao C, Xin D, Ogurek S, Liu X, Zhang L, Luo Z, Sakabe M, Trubicka J, Łastowska M, Szulzewsky F, Holland EC, Lee L, Hu M, Xin M, Lu QR. Nuclear condensates of YAP fusion proteins alter transcription to drive ependymoma tumourigenesis. Nat Cell Biol 2023; 25: 323-336.
13.
Kim BG, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ. Novel therapies emerging in oncology to target the TGF-beta pathway. J Hematol Oncol 2021; 14: 55.
14.
Li AM, Dunham C, Tabori U, Carret AS, McNeely PD, Johnston D,Lafay-Cousin L, Wilson B, Eisenstat DD, Jabado N, Zelcer S, Silva M, Scheinemann K, Fryer C, Hendson G, Fotovati A, Hawkins C, Yip S, Dunn SE, Hukin J. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study. Cancer 2015; 121: 1499-1507.
15.
Liu L, Li Q, Yang L, Li Q, Du X. SMAD4 Feedback Activates the Canonical TGF-beta Family Signaling Pathways. Int J Mol Sci 2021; 22.
16.
Liu Z, Qi T, Li X, Yao Y, Othmane B, Chen J, Zu X, Ou Z, Hu J. A novel TGF-beta risk score predicts the clinical outcomes and tumour microenvironment phenotypes in bladder cancer. Front Immunol 2021; 12: 791924.
17.
McGuire CS, Sainani KL, Fisher PG. Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurg 2009; 110: 725-729.
18.
Mikula-Pietrasik J, Rutecki S, Ksiazek K. The functional multipotency of transforming growth factor beta signaling at the intersection of senescence and cancer. Cell Mol Life Sci 2022; 79: 196.
19.
Morikawa M, Derynck R, Miyazono K. TGF-beta and the TGF-beta family: Context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol 2016; 8: a021873.
20.
Pasche B, Pennison MJ, Jimenez H, Wang M. TGFBR1 and cancer susceptibility. Trans Am Clin Climatol Assoc 2014; 125: 300-312.
21.
Ruda R, Bruno F, Pellerino A, Soffietti R. Ependymoma: evaluation and management updates. Curr Oncol Rep 2022; 24: 985-993.
22.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504.
23.
Tauziede-Espariat A, Siegfried A, Nicaise Y, Figarella-Branger D,Appay R, Senova S, Bochaton D, Hasty L, Martin A, Chrétien F,Métais A, Varlet P, Uro-Coste E; RENOCLIP-LOC. A novel YAP1-MAML2 fusion in an adult supra-tentorial ependymoma, YAP1-fused. Brain Tumor Pathol 2022; 39: 240-242.
24.
Todd GM, Gao Z, Hyvonen M, Brazil DP, Dijke PT. Secreted BMP antagonists and their role in cancer and bone metastases. Bone 2020; 137: 115455.
25.
Tzavlaki K, Moustakas A. TGF-beta signaling. Biomolecules 2020; 10.
26.
Ungefroren H. Blockade of TGF-beta signaling: a potential target for cancer immunotherapy? Expert Opin Ther Targets 2019; 23: 679-693.
27.
von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B.STRING: a database of predicted functional associations between proteins. Nucleic Acids Res 2003; 31: 258-261.
28.
Wang G, Jia Y, Ye Y, Kang E, Chen H, Wang J, He X. Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis. J Transl Med 2021; 19: 174.
29.
Wang Q, Xiong F, Wu G, Wang D, Liu W, Chen J, Qi Y, Wang B, Chen Y. SMAD Proteins in TGF-beta Signalling Pathway in Cancer: Regulatory Mechanisms and Clinical Applications. Diagnostics (Basel) 2023; 13: 2769.
30.
Yang B, Dai JX, Pan YB, Ma YB, Chu SH. Identification of biomarkers and construction of a microRNA-mRNA regulatory network for ependymoma using integrated bioinformatics analysis. Oncol Lett 2019; 18: 6079-6089.
31.
Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012; 16: 284-287.
